Published in final edited form as:

Tetrahedron Lett. 2012 September 5; 53(36): 4870–4872. doi:10.1016/j.tetlet.2012.06.139.

Multi-component synthesis of 2-amino-6-(alkylthio)pyridine-3,5-dicarbonitriles using Zn(II) and Cd(II) metal-organic frameworks (MOFs) under solvent-free conditions

Muralidhara Thimmaiah[†], Peng Li[†], Sridhar Regati[†], Banglin Chen, and John Cong-Gui Zhao

Department of Chemistry, University of Texas at San Antonio, One UTSA Circle, San Antonio, Texas 78249-0698

Banglin Chen: banglin.chen@utsa.edu; John Cong-Gui Zhao: cong.zhao@utsa.edu

Abstract

Multi-component synthesis 2-amino-3,5-dicarbonitrile-6-thio-pyridines has been developed by using the reaction of aldehydes, malononitrile, and thiophenols in the presence of a Zn (II) or a Cd(II) metal-organic framework (MOF) as the heterogeneous catalyst. This protocol tolerates different functional groups on the substrates and does not require the use of any organic solvent. Moreover, the Zn(II) and Cd (II) MOF catalysts can be recovered and reused for a number of runs without loss of activity.

Keywords

Metal-organic frameworks; Multi-component reaction; Heterogeneous catalysis; Benzaldehyde; Pyridine

Among the nitrogen-containing heterocycles, densely substituted pyridine derivatives are one of the most important classes of compounds as they widely occur as key structural subunits in numerous natural products that exhibit many interesting biological activities.¹ In addition, these heterocyclic compounds have found a variety of applications in medicinal and pharmaceutical sciences.² Among these pyridine derivatives, 2-amino-6-(arylthio)pyridine-3,5-dicarbonitrile is a privileged scaffold for developing pharmaceutical agents because various compounds with this structural motif display significant and diverse biological activities. For examples, adenosine receptors are associated with Parkinson's disease, hypoxia, asthma, epilepsy, cancer, and cardiovascular diseases.³ These pyridine compounds have been shown to be active inhibitors of the adenosine receptors and, therefore, can be used for treating these diseases.³ They are also inhibitors of cholinesterases and may be used for treating neurodegenerative diseases.⁴ These compounds have also been studied as potential anti-HBV,⁵ anti-bacterial, antibiofilm, and anti-infective agents⁶ and as

© 2012 Elsevier Ltd. All rights reserved.

[†]These authors contributed equally to this work.

Supplementary data

Supplementary data (characterization data and copy of NMR spectra of the multi-component reaction products) associated with this article can be found, in the online version at doi:

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

potassium channel openers with applications in treating urinary incontinence.⁷ Moreover, some of these derivatives also inhibit prion replication and may be used for treating Creutzfeldt–Jacob disease.⁸ A few examples of recently reported biologically significant 2-amino-6-(alkylthio)pyridine-3,5-dicarbonitrile derivatives are collected in Figure 1. Compound **1** is an agonist for adenosine A₁ receptor,^{3c} while compound **2** is a highly potent agonist for human adenosine A_{2B} receptor.^{3b} Compounds **3**^{8b} and **4**^{8a} have been proposed as potential therapeutics for prion disease due to their ability in inhibiting prion replication.⁸

Owing to the broad spectrum of biological activities exhibited by these 2-amino-6-thiopyridine-3,5-dicarbonitrile derivatives, many synthetic methods have been developed for the construction of these compounds.⁹ Among these reported methods, the Lewis/Brønsted base-catalyzed three-component reaction of aldehydes, malononitrile and thiophenols is the most common approach.⁹ The reported Lewis/Brønsted base catalysts include DBU,^{9f} Et₃N,^{9b,9d} piperidine,^{9e,h} KF/alumina,^{9j,k} and K₂CO₃/KMnO₄,^{9p} etc. Besides bases, Lewis acid, Brønsted acid, nanoparticles, and ionic liquids, such as ZnCl₂,^{9g} boric acid,^{9l} silica nanoparticles,⁹ⁱ nano MgO,^{9m} [bmim]OH,^{9c} and [bmim]Br,^{9o} are also occasionally used. Good to high yields of the desired 2-amino-3,5-dicarbonitrile-6-thio-pyridines may be obtained using these methods. Nevertheless, most of these methods require the use of hazardous organic solvents, and some of them need exotic reaction conditions such as the use of microwave irradiation or an ionic liquid. Because of our continuing interest in developing green methods for the synthesis of biologically significant molecules,¹⁰ the development of an environmentally benign and practical synthetic route for accessing these important pyridine derivatives became our goal.

Metal-organic frameworks (MOFs)^{11,12} have been shown to be a class of emerging catalysts with many promising characters. These new heterogeneous catalysts usually are very stable and may be easily recycled and reused after the application. Recently we have reported the synthesis of two new iso-structural Zn- and Cd-based MOFs M(4,4'-Bpe)₂(H₂O)₄•(*m*-BDS) (M = Zn²⁺ and Cd²⁺; 4,4'-Bpe = 1,2-bis(4-pyridyl)ethylene; *m*-BDS = 1,3-benzenedisulfonic acid) and their application as robust and green catalysts for the Biginelli reaction.¹³ In continuation of our interest in MOF-catalyzed reactions, we recently explored the synthesis of 2-amino-6-(arylthio)pyridine-3,5-dicarbonitriles using a multi-component reaction of aldehyde, malononitrile, and thiophenol catalyzed by these Zn(II) and Cd(II) MOFs. Once again we demonstrated the remarkable catalytic activity of these robust MOF catalysts. Herein we wish to report our findings.

Benzaldehyde (**1a**), malononitrile (**2**), and thiophenol (**3a**) were adopted as the model substrates for investigating the multi-component synthesis of 2-amino-6-(arylthio)pyridine-3,5-dicarbonitriles. The Zn(II) and Cd(II) MOFs developed in our lab were used as the catalysts.¹³ The results of the optimizations are summarized in Table 1.

Initial screenings were performed using toluene as a solvent. In the absence of catalyst, the product was obtained in only 30% yield after refluxing for 16 h (Table 1, entry 1). In contrast, in the presence of only a catalytic amount (2.0 mol %) of the Zn(II) and Cd(II) MOFs, after 10 h, the desired product was obtained in high yields of 82 and 84%, respectively (Table 1, entries 2 and 3). When the reactions were performed under solvent-free conditions, the reaction times were decreased to 30 minutes with the same catalyst loading (Table 1, entries 4 and 5).¹⁴ This is a great advantage of this new catalytic system in terms of green chemistry since no toxic organic solvent is required for realizing the desired transformation.

In order to demonstrate the scope of this reaction, a series of substituted aldehydes and thiophenols were then studied and the results are summarized in Table 2. As is evident from

the results in Table 2 show, this method is highly compatible with many substituted benzaldehydes. Benzaldehydes with both an electron-donating and an electron-withdrawing group, such as, 4-fluoro, 4-chloro, 4-nitro, 4-methyl, and 4-methoxy groups, all give the desired products in excellent yields (Table 2, entries 2–6 and 13–17). In addition, good to high yields were also obtained for a heteroaromatic aldehyde (thiophene-2-carbaldehyde, entries 7 and 18) and an aliphatic aldehyde (*n*-hexanal, entries 8 and 19) when they were applied in this reaction. Similarly, the substituents on the thiophenol show almost no effects on the reaction: 4-Chloro, 4-methyl, and 4-methoxy substituted thiols afforded the corresponding pyridine derivatives in good to excellent yields with both catalysts (Table 2, entries 9–11 and 20–22).

The other advantage of these heterogeneous MOF catalysts lies in the fact that they may easily be recovered by simple filtrations and can be reused for many cycles without significant loss of the catalytic activities. As our results in Table 3 show, when the reaction of benzaldehyde (**1a**), malononitrile (**2**) and thiophenol (**3a**) was used as a model reaction, both the Zn(II) and the Cd(II) MOF's can be recovered in high yields and reused for five cycles with almost no loss of the catalytic activity for the first three cycles (Table 3, entries 1–10).

In summary, we have demonstrated that the Zn(II) and Cd(II) MOFs are efficient, robust, and recyclable catalysts for the multi-component reaction of aldehydes, malononitrile, and thiophenols. This reaction offers a new convenient and green method for the synthesis of the biologically significant 6-(alkylthio)-2-amino-pyridine-3,5-dicarbonitrile derivatives. These MOF-mediated green reactions are mild and easy to operate with the advantage of the solvent-free reaction conditions.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

BC thanks the financial support of this research from the Welch Foundation (Grant No. AX-1730). JCZ thanks the generous financial support of this research from the National Institutes of Health-National Institute of General Medical Sciences (Grant no. SC1GM082718) and the Welch Foundation (Grant No. AX-1593).

References and notes

- (a) Cocco MT, Congiu C, Lilliu V, Onnis V. *Eur J Med Chem.* 2005; 40:1365. [PubMed: 16137795] (b) Boger DL, Nakahara S. *J Org Chem.* 1991; 56:880. (c) Boger DL, Kasper AM. *J Am Chem Soc.* 1989; 111:1517. (d) Zhang TY, Stout JR, Keay JG, Scriven EFV, Toomey JE, Goe GL. *Tetrahedron.* 1995; 51:13177.
- Ma X, Gang DR. *Nat Prod Rep.* 2004; 21:752. [PubMed: 15565253]
- (a) May BCH, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE. *J Med Chem.* 2007; 50:65. [PubMed: 17201410] (b) Beukers MW, Chang LCW, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, Spanjersberg RF, Brussee J, Ijzerman AP. *J Med Chem.* 2004; 47:3707. [PubMed: 15239649] (c) Chang LCW, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, Spanjersberg RF, Roerink SF, van den Hout G, Beukers MW, Brussee J, Ijzerman AP. *J Med Chem.* 2005; 48:2045. [PubMed: 15771447] (d) Vakalopoulos, A.; Meibom, D.; Nell, P.; Suessmeier, F.; Albrecht-Kuepper, B.; Zimmermann, K.; Keldenich, J.; Schneider, D.; Krenz, U. *PCT Int Appl. WO 2012000945 A1.* 2012. (e) Rosentreter, U.; Kraemer, T.; Vaupel, A.; Huebsch, W.; Diedrichs, N.; Krahn, T.; Dembowski, K.; Stasch, J-P. *PCT Int Appl. WO 2002070520 A1.* 2002.
- (a) Samadi, A.; Chioua, M.; Alvarez Perez, M.; Soriano Santamaria, E.; Valderas Cortina, C.; Marco Contelles, JL.; De Los Rios, SC.; Romero Martinez, A.; Villarroja Sanchez, M.; Garcia Lopez, M.;

- Garcia Garcia, A. Span. ES 2365233 A1. 2011. (b) Samadi A, Marco-Contelles J, Soriano E, Alvarez-Perez M, Chioua M, Romero A, Gonzalez-Lafuente L, Gandia L, Roda JM, Lopez MG, Villarroya M, Garcia AG, de los Rios C. *Bioorg Med Chem*. 2010; 18:5861. [PubMed: 20656495]
5. (a) Chen, H.; Zhang, W.; Tam, R.; Raney, AK. PCT Int Appl. WO 2005058315 A1. 2005. (b) Fredholm BB, Ijzerman AP, Jacobson KA, Klotz K-N, Linden J. *Pharmacol Rev*. 2001; 53:527. [PubMed: 11734617]
 6. Levy, SB.; Alekshun, MN.; Podlogar, BL.; Ohemeng, K.; Verma, AK.; Warchol, T.; Bhatia, B.; Bowser, T.; Grier, M. US Pat Appl Publ. US 2005124678 A1. 2005.
 7. Harada, H.; Watanuki, S.; Takuwa, T.; Kawaguchi, K.; Okazaki, T.; Hirano, Y.; Saitoh, C. PCT Int Appl. WO 2002006237 A1. 2002.
 8. (a) Perrier V, Wallace AC, Kaneko K, Safar J, Prusiner SB, Cohen FE. *Proc Nat Acad Sci USA*. 2000; 97:6073. [PubMed: 10823951] (b) Reddy TRK, Mutter R, Heal W, Guo K, Gillet VJ, Pratt S, Chen B. *J Med Chem*. 2006; 49:607. [PubMed: 16420046] (c) Guo K, Mutter R, Heal W, Reddy TRK, Cope H, Pratt S, Thompson MJ, Chen B. *Eur J Med Chem*. 2008; 43:93. [PubMed: 17475368]
 9. For examples, see: Kambe S, Saito K, Sakurai A, Midorikawa H. *Synthesis*. 1981:531. Evdokimov NM, Magedov IV, Kireev AS, Kornienko A. *Org Lett*. 2006; 8:899. [PubMed: 16494469] Ranu BC, Jana R, Sowmiah S. *J Org Chem*. 2007; 72:3152. [PubMed: 17367198] Evdokimov NM, Kireev AS, Yakovenko AA, Antipin MY, Magedov IV, Kornienko A. *J Org Chem*. 2007; 72:3443. [PubMed: 17408286] Guo K, Thompson MJ, Reddy TRK, Mutter R, Chen B. *Tetrahedron*. 2007; 63:5300. Mamgain R, Singh R, Rawat DS. *J Heterocycl Chem*. 2009; 46:69. Sridhar M, Ramanaiah BC, Narsaiah C, Mahesh B, Kumaraswamy M, Mallu KKR, Ankathi VM, Rao PS. *Tetrahedron Lett*. 2009; 50:3897. Guo K, Thompson MJ, Chen B. *J Org Chem*. 2009; 74:6999. [PubMed: 19678630] Banerjee S, Sereda G. *Tetrahedron Lett*. 2009; 50:6959. Das B, Ravikanth B, Kumar AS, Kanth BS. *J Heterocycl Chem*. 2009; 46:1208. Singh KN, Singh SK. *ARKIVOC*. 2009; 13:153. Shinde PV, Sonar SS, Shingate BB, Shingare MS. *Tetrahedron Lett*. 2010; 51:1309. Kantam ML, Mahendar K, Bhargava S. *J Chem Sci*. 2010; 122:63. Poor Heravi MR, Fakhr F. *Tetrahedron Lett*. 2011; 52:6779. Davoodnia A, Attar P, Eshghi H, Morsali A, Tavakoli-Hoseini N, Tavakoli-Nishaburi A. *Asian J Chem*. 2011; 23:1273. Mishra S, Ghosh R. *Synth Commun*. 2012; 42:2229.
 10. (a) Bhanushali M, Zhao C-G. *Synthesis*. 2011:1815. [PubMed: 21918584] (b) Ding D, Zhao C-G. *Eur J Org Chem*. 2010:3802. (c) Gogoi S, Zhao CG. *Tetrahedron Lett*. 2009; 50:2252. [PubMed: 19915654]
 11. For reviews, see: Leadbeater NE, Marco M. *Chem Rev*. 2002; 102:3217. [PubMed: 12371884] Song CE, Lee SG. *Chem Rev*. 2002; 102:3495. [PubMed: 12371891] Van Heerbeek R, Kamer PCJ, Van Leeuwen PWNM, Reek JNH. *Chem Rev*. 2002; 102:3717. [PubMed: 12371900]
 12. For reviews, see: Ma L, Abney C, Lin W. *Chem Soc Rev*. 2009; 38:1248. [PubMed: 19384436] Lee JY, Farha OK, Roberts J, Scheidt KA, Nguyen SBT, Hupp JT. *Chem Soc Rev*. 2009; 38:1450. [PubMed: 19384447] Ma L, Lin W. *Top Curr Chem*. 2010; 293:175. [PubMed: 21618746] Jiang HL, Xu Q. *Chem Commun*. 2011; 47:3351. Shi LX, Wu CD. *Chem Commun*. 2011; 47:2928. Corma A, Garcia H, Llabres I, Xamena FX. *Chem Rev*. 2010; 110:4606. [PubMed: 20359232] Zou C, Wu CD. *Dalton Trans*. 2012; 41:3879. [PubMed: 22318342] Yoon M, Srirambalaji R, Kim K. *Chem Rev*. 2012; 112:1196. [PubMed: 22084838] Zhu C, Yuan G, Chen X, Yang Z, Cui Y. *J Am Chem Soc*. 2012; 134:8058. [PubMed: 22545656]
 13. Li P, Regati S, Butcher RJ, Arman HD, Chen Z, Xiang S, Chen B, Zhao C-G. *Tetrahedron Lett*. 2011; 52:6220. [PubMed: 22043110]
 14. **General Experimental Procedures:** To a mixture of benzaldehyde (**1a**, 21.2 mg, 0.20 mmol), malononitrile (**2**, 19.8 mg, 0.30 mmol), and thiophenol (**3a**, 11.0 mg, 0.10 mmol) was added the Zn(II) MOF (1.5 mg, 0.0020 mmol, 2.0 mol %) or the Cd (II) MOF (1.6 mg, 0.0020 mmol, 2.0 mol %). The mixture was then kept at 100 °C for 30 min until the full conversion of the starting materials was achieved (monitored by TLC). The reaction mixture was then filtered and washed with hot ethanol to recover the catalyst. The filtrate was stripped of the solvent and then purified using column chromatography to give the desired product **4a** (28.1 mg, 86% for Zn(II) MOF and 28.5 mg, 87% for Cd(II) catalyst, respectively).

Figure 1.
Examples of biologically active 2-amino-6-(aryltio)pyridine-3,5-dicarbonitriles

Table 1

Reaction condition optimizations^a

Entry	MOF	T (°C)	Solvent	Time (h)	Yield (%) ^b
1 ^c	---	reflux	Toluene	16	30
2	Zn	reflux	Toluene	10	82
3	Cd	reflux	Toluene	10	84
4	Zn	100	Neat	0.5	86
5	Cd	100	Neat	0.5	87

^aUnless otherwise specified, all reactions were carried out with **1a** (0.20 mmol), **2** (0.30 mmol), and **3a** (0.10 mmol) and the MOF catalyst (0.0020 mmol, 2.0 mol %).

^bYield of the isolated product after column chromatography.

^cWithout any catalyst.

Table 2

Multi-component synthesis of 2-amino-6-thiopyridine-3,5-dicarbonitriles catalyzed by Zn-MOF and Cd-MOF^a

Entry	MOF	R ¹	R ²	Time (min)	Yield (%) ^b
1	Zn	Ph	Ph	30	86
2	Zn	4-FC ₆ H ₄	Ph	30	80
3	Zn	4-ClC ₆ H ₄	Ph	30	86
4	Zn	4-NO ₂ C ₆ H ₄	Ph	30	87
5	Zn	4-MeC ₆ H ₄	Ph	45	79
6	Zn	4-MeOC ₆ H ₄	Ph	45	73
7	Zn	2-Thiophenyl	Ph	40	83
8	Zn	<i>n</i> -C ₅ H ₁₁	Ph	60	61
9	Zn	Ph	4-ClC ₆ H ₄	40	87
10	Zn	Ph	4-MeC ₆ H ₄	30	80
11	Zn	Ph	4-MeOC ₆ H ₄	30	81
12	Cd	Ph	Ph	30	87
13	Cd	4-FC ₆ H ₄	Ph	30	82
14	Cd	4-ClC ₆ H ₄	Ph	30	87
15	Cd	4-NO ₂ C ₆ H ₄	Ph	30	88
16	Cd	4-MeC ₆ H ₄	Ph	45	81
17	Cd	4-MeOC ₆ H ₄	Ph	45	73
18	Cd	2-Thiophenyl	Ph	40	85
19	Cd	<i>n</i> -C ₅ H ₁₁	Ph	60	61
20	Cd	Ph	4-ClC ₆ H ₄	40	87
21	Cd	Ph	4-MeC ₆ H ₄	30	81
22	Cd	Ph	4-MeOC ₆ H ₄	30	84

^aUnless otherwise specified, all reactions were carried out with **1** (0.2 mmol), **2** (0.3 mmol), and **3** (0.1 mmol) and the MOF catalyst (0.002 mmol, 2.0 mol %) under neat conditions.

^bYield of the isolated product after column chromatography.

Table 3

Catalyst recycling and stability study^a

Entry	MOF	T (°C)	Cycle	Catalyst recovery (%)	Time (min)	Yield (%) ^b
1	Zn ^c	100	I	99	30	86
2	Zn ^d	100	II	97	30	85
3	Zn ^e	100	III	94	40	83
4	Zn ^f	100	IV	93	50	81
5	Zn ^g	100	V	90	60	79
6	Cd ^c	100	I	>99	30	87
7	Cd ^d	100	II	98	30	85
8	Cd ^e	100	III	96	30	84
9	Cd ^f	100	IV	94	40	81
10	Cd ^g	100	V	91	50	80

^aUnless otherwise specified, all reactions were carried out with **1a** (0.20 mmol), **2a** (0.10 mmol), and **3a** (0.0020 mmol, 2.0 mol %) under neat conditions.

^bYield of the isolated product after column chromatography.

^cThe scale of this reaction was 8.0 mmol.

^dThe scale of this reaction was 7.0 mmol.

^eThe scale of this reaction was 6.0 mmol.

^fThe scale of this reaction was 5.0 mmol.

^gThe scale of this reaction was 4.0 mmol.